A former director of the Congressional Budget Office (CBO) told Inside Health Policy that President Donald Trump’s proposal to impose tariffs on pharmaceutical products to boost U.S. manufacturing is unrealistic, arguing that ramping up domestic production would take years and tariffs could ultimately strengthen China’s drug market as U.S. companies shift sales overseas. Other experts cautioned that the tariffs could drive up U.S. drug prices and exacerbate the ongoing drug shortage crisis. At a congressional Republican retreat in Miami...